Drug-Induced Liver Injury (DILI)
studying new diagnostic markers in patients with drug induced liver
injury (DILI) that will allow
earlier and more specific diagnosis of hepatic injury caused by therapeutic
drugs. These studies are conducted in collaboration with the following
consortia: (i) IDILIC (International
Drug Induced Liver Injury Consortium), for the analysis of genetic risk factors
by genome-wide association studies; (ii) TransBioLine Consortium,
supported by the Innovative Medicines Initiative of the European Union.
are treating a patient with suspected liver injury caused by a drug or a herbal
remedy, please contact us for further information on how to include the patient
in the Swiss DILI Cohort Study. Liver injury is defined by any one of the
with documentation of normal values before beginning the
drug that is suspected to have caused injury.
Prof. Gerd Kullak-Ublick (firstname.lastname@example.org), phone +41
44 255 20 68